Combining a hedgehog pathway inhibitor, sonidegib, with JAK2 inhibition in a murine MF transplant model resulted in reduction of leukocytes, platelets, mutant allele burden, and bone marrow fibrosis, providing evidence that this pathway may be a therapeutic target for MPN [101]. This evidence concerns the gene JAK2 and myeloproliferative disorder.